AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company.
坎託·菲茨傑拉德已開始對全球製藥公司艾伯維公司（紐約證券交易所代碼：ABBV）進行報道。
The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.
分析師指出，該公司已將自己定位爲吸收Humira生物仿製藥的侵蝕並實現適度的運營收入增長。
Related: Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook.
相關： 前Humira增長平台推動了AbbVie第一季度的業績，製藥商上調了年度利潤展望。
Cantor expects robust growth to resume in 2025, with projections aligning with management's long-term guidance of a high single-digit compound annual growth rate (CAGR) from 2024 to 2029.
坎託預計，2025年將恢復強勁增長，預測與管理層的長期指導一致，即從2024年到2029年將實現較高的個位數複合年增長率（CAGR）。
This forecast follows one of the largest losses of exclusivity (LOE) in the pharmaceutical industry.
該預測是在製藥行業最大的獨家經營權（LOE）損失之一之後作出的。
The analyst has initiated the coverage with an Overweight rating, with a price target of $200.
該分析師以增持評級啓動了報道，目標股價爲200美元。
Cantor expects that Bristol-Myers Squibb Co (NYSE:BMY), which acquired Karuna Therapeutics' KarXT, will likely come to market before AbbVie's antipsychotic emraclidine and become the leading drug.
坎託預計，收購Karuna Therapeutics的KarXt的百時美施貴寶公司（紐約證券交易所代碼：BMY）很可能會在艾伯維的抗精神病藥物依姆拉利定之前上市，成爲領先的藥物。
The analyst notes that if emraclidine's Phase 2 studies show a similar reduction in PANSS to what was seen in Phase 1, physicians think that emraclidine will win over KarXT.
分析師指出，如果emraclidine的2期研究顯示PANSS的下降幅度與第一階段相似，那麼醫生認爲依姆拉利定將戰勝KarXT。
Positive and Negative Syndrome Scale (PANSS) is used to assess antipsychotic treatment efficacy.
陽性和陰性綜合徵量表（PANSS）用於評估抗精神病藥物治療的療效。
"When we compare the two products, we believe emraclidine differentiates by its dosing frequency (QD vs. BD), better GI safety profile, and potentially greater efficacy (PANSS score)," Cantor writes.
坎託寫道：“當我們比較這兩種產品時，我們認爲依姆拉利定的區別在於其給藥頻率（QD 與 BD）、更好的胃腸道安全性以及可能更高的療效（PANSS評分）。”
The analyst says the peak sales potential of Skyrizi, Rinvoq, emraclidine, and AbbVie's pipeline is underappreciated, and Humira's tail will be manageable at $4 billion—$5 billion in annual sales.
這位分析師表示，Skyrizi、Rinvoq、emraclidine和AbbVie產品線的峯值銷售潛力被低估了，而Humira的尾巴將保持在40億美元至50億美元的年銷售額水平。
AbbVie is advancing its second wave of Rinvoq development programs, with Phase 3 studies ongoing for five new indications: giant cell arteritis, lupus, hidradenitis suppurativa, alopecia areata, and vitiligo.
艾伯維正在推進其第二波Rinvoq開發計劃，目前正在對五種新適應症進行三期研究：鉅細胞動脈炎、狼瘡、化膿性汗腺炎、脫髮和白癜風。
The company expects to release data from these studies within the next three years. These new indications could generate several billion dollars in peak sales, indicating substantial growth potential for Rinvoq beyond 2027.
該公司預計將在未來三年內發佈這些研究的數據。這些新跡象可能帶來數十億美元的峯值銷售額，表明Rinvoq在2027年以後的巨大增長潛力。
Price Action: ABBV shares were up 1.10% at $166.16 at last check on Friday.
價格走勢：週五最後一次查看時，ABBV股價上漲1.10％，至166.16美元。
Photo via Company
照片來自公司
譯文內容由第三人軟體翻譯。